Back to Clinical Trials

Brief Title: Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

Randomized Controlled Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

INTRODUCTION

  • Org Study ID: iRISID-2025-0635
  • Secondary ID: N/A
  • NCT ID: NCT07234968
  • Sponsor: Thomas Jefferson University

BRIEF SUMMARY

Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the standard of care and be enrolled in the study for 12 months post-op. Risk of post-op complications will be analyzed.

DETAILED DESCRIPTION

Patients who are indicated for RCIC will be recruited for this prospective RCT. Ureteral stents will be placed intraoperatively and removed at follow-up visit per surgeon discretion. Either approach would be considered standard of care for muscle invasive bladder cancer, for which radical cystectomy with urinary diversion is the gold standard of treatment.

Patients will be randomized 1:1 to receive stent or no stent during RCIC (Stent: N=35, No Stent: N=35). Randomization will be stratified by surgical approach (open vs. robotic vs. hybrid). The randomization schedule will be created by the study statistician using the method of random permuted blocks.

Stent placement, if applicable, will be a one-time occurrence inserted during RCIC, and be removed typically between 7-21 days post-op at the discretion of the surgeon. For this study, subjects will continue to be followed for up to 1-year post-op. Subjects will be enrolled in this study for 12 months.

Post treatment, the patient will have a follow-up visit within 30 days post-operatively, 3 months follow-up visit (+/- 1 week), 6 months follow-up visit (+/- 21 days), and 12 months follow-up visit (+/- 21 days). Patient will be followed for 12 months post treatment or until their death. Additional visits or follow-ups may be indicated for instances of the need for replacement of ureteral stents and catheters or percutaneous nephrostomies. The need for surgical repair for a ureteral leak or stricture may also occur.

The Principal Investigator hypothesizes that patients with no ureteral stent placement during RCIC will not be associated with a higher risk of post-op complications compared to those with a ureteral stent.

  • Overall Status
    Recruiting
  • Start Date
    December 23, 2025
  • Phase
    Not Applicable
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Number of urinary tract infection (UTI)

Primary Outcome 1 - Timeframe: 90 days after surgery

CONDITION

  • Bladder Cancer
  • Muscle-Invasive Bladder Carcinoma
  • Urothelial Carcinoma
  • Pelvic Malignancy
  • Bladder Transitional Cell Carcinoma
  • Bladder Neoplasm

ELIGIBILITY

Inclusion Criteria:
* Individuals must meet all the following inclusion criteria to be eligible to participate in the study:
* Provide signed and dated informed consent form

- * Willing to comply with all study procedures and be available for the duration of the study

- * Male or female, age 18 to 85

- * Diagnosed with bladder cancer, other pelvic malignancies necessitating a cystectomy (e.g.: colorectal, prostate, gynecologic) and have elected for a cystectomy with ileal conduit urinary diversion
Exclusion Criteria:
* An individual who meets any of the following criteria will be excluded from participation in this study:
* Current or history of pelvic radiation

- * Retroperitoneal fibrosis

- * Untreated urinary tract infection (UTI) within 30 days prior to RCIC

- * Pregnancy

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Mihir S Shah, MD

Role: Principal Investigator

Affiliation: Thomas Jefferson University

Overall Contact

Name: Mihir S Shah, MD

Phone: 215-955-6961

Email: [email protected]

LOCATION

Facility Status Contact
Facility: Thomas Jefferson University Hospital
Philadelphia, Pennsylvania 19107
United States
Status: Recruiting Contact: Contact
Mihir S Shah, MD
215-955-6961